MarketCap
Facebook
X
Telegram
IGM Biosciences Total Liabilities | IGMS
Annual Total Liabilities IGM Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 218 M | 220 M | 226 M | 53.2 M | 26.8 M | 21.1 M | 69.8 M | 41.9 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 226 M | 21.1 M | 110 M |
Quarterly Total Liabilities IGM Biosciences
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.06 M | 206 M | 226 M | 214 M | 215 M | 220 M | 222 M | 223 M | 226 M | 213 M | 207 M | 53.2 M | 53.2 M | 46.7 M | 28.2 M | 24.9 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | 21.1 M | 21.1 M | 21.1 M | 21.1 M | 8.89 M | 8.89 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 226 M | 6.06 M | 99.8 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Eiger BioPharmaceuticals
EIGR
|
53.3 M | - | -9.21 % | $ 2.55 M |  USA |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
BELLUS Health
BLU
|
16.8 M | - | - | $ 2.47 B |  Canada |
 |
bluebird bio
BLUE
|
492 M | - | - | $ 546 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
218 M | - | - | $ 13.6 B | USA |
 |
Marinus Pharmaceuticals
MRNS
|
154 M | - | - | $ 29.6 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
441 K | - | - | $ 216 M | USA |
 |
CASI Pharmaceuticals
CASI
|
29.3 M | - | - | $ 35.4 M | USA |
 |
ContraFect Corporation
CFRX
|
32.5 M | - | -5.16 % | $ 5.39 M | USA |
 |
Sigilon Therapeutics
SGTX
|
48.1 M | - | - | $ 728 M | USA |
 |
Rubius Therapeutics
RUBY
|
7.94 M | - | -33.55 % | $ 7.81 M | USA |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
TRACON Pharmaceuticals
TCON
|
15.4 M | - | -1.38 % | $ 46.8 M | USA |
 |
Mirati Therapeutics
MRTX
|
206 M | - | - | $ 3.3 B | USA |
 |
Revance Therapeutics
RVNC
|
630 M | - | - | $ 309 M | USA |
 |
Allogene Therapeutics
ALLO
|
123 M | $ 1.03 | -5.5 % | $ 227 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
3.08 M | - | -37.48 % | $ 476 K | USA |
 |
Epizyme
EPZM
|
289 M | - | - | $ 249 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | USA |
 |
ORIC Pharmaceuticals
ORIC
|
24.5 M | $ 8.87 | 4.48 % | $ 779 M | USA |
 |
Forward Pharma A/S
FWP
|
1.07 M | - | -0.75 % | $ 18.7 M |  Danmark |
 |
Orchard Therapeutics plc
ORTX
|
121 M | - | 1.02 % | $ 90.8 M |  Britain |
 |
La Jolla Pharmaceutical Company
LJPC
|
168 M | - | - | $ 154 M | USA |
 |
Oyster Point Pharma
OYST
|
123 M | - | - | $ 300 M | USA |
 |
Nabriva Therapeutics plc
NBRV
|
28.5 M | - | - | $ 4.55 M |  Irlanda |
 |
Intercept Pharmaceuticals
ICPT
|
461 M | - | - | $ 643 M | USA |
 |
NGM Biopharmaceuticals
NGM
|
20.2 M | - | - | $ 127 M | USA |
 |
Regulus Therapeutics
RGLS
|
7.77 M | - | - | $ 155 M | USA |
 |
9 Meters Biopharma
NMTR
|
30.7 M | - | -42.97 % | $ 1.05 M | USA |
 |
Chinook Therapeutics
KDNY
|
132 M | - | - | $ 2.6 B | USA |
 |
Lumos Pharma
LUMO
|
13.3 M | - | - | $ 35.3 M | USA |
 |
Syros Pharmaceuticals
SYRS
|
70.8 M | - | -8.44 % | $ 3.4 M | USA |
 |
NanoViricides
NNVC
|
1.2 M | $ 1.32 | 2.33 % | $ 26.6 M | USA |
 |
Gamida Cell Ltd.
GMDA
|
56.7 M | - | -18.25 % | $ 5.04 M |  Israel |
 |
GT Biopharma
GTBP
|
1.32 M | $ 4.42 | -2.64 % | $ 24.4 M | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | USA |
 |
Omeros Corporation
OMER
|
246 M | $ 16.91 | -1.11 % | $ 1.07 B | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
156 B | $ 14.9 | 2.58 % | $ 12.4 B |  India |
 |
C4 Therapeutics
CCCC
|
102 M | $ 3.09 | 4.75 % | $ 256 M | USA |
|
Phathom Pharmaceuticals
PHAT
|
697 M | $ 5.24 | 3.05 % | $ 382 M | USA |
 |
Protalix BioTherapeutics
PLX
|
34.1 M | $ 2.51 | 1.0 % | $ 197 M | Israel |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
32 M | $ 4.8 | 4.35 % | $ 40.9 M | USA |
 |
PTC Therapeutics
PTCT
|
3.1 B | $ 65.94 | 0.41 % | $ 5.24 B | USA |
 |
Celldex Therapeutics
CLDX
|
55.8 M | $ 29.89 | 5.71 % | $ 1.99 B | USA |
 |
Pulmatrix
PULM
|
905 K | $ 1.42 | 1.36 % | $ 5.19 B | USA |
 |
Arcus Biosciences
RCUS
|
39.3 M | $ 18.27 | 3.28 % | $ 1.96 B | USA |
 |
Sana Biotechnology
SANA
|
256 M | $ 2.41 | 2.99 % | $ 610 M | USA |
 |
Vir Biotechnology
VIR
|
238 M | $ 12.27 | 11.34 % | $ 1.7 B | USA |